Key Takeaways Corcept shares have surged 39.6% in 2025, beating the industry, sector, and S&P 500.CORT's relacorilant NDA for Cushing's syndrome was accepted, with FDA decision set for Dec. 30, 2025.Corcept also filed an NDA for relacorilant in ovarian cancer after positive phase III ROSELLA data.Corcept Therapeutics (CORT) has delivered a strong performance in the year-to-date period. Shares of the company have rallied 39.6% compared with the industry’s rise of 10.2%. The stock has also outperformed the se ...